menu
    • menu
    [{"orgOrder":0,"company":"SmartCella","sponsor":"Fj\u00e4rde AP-fonden","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Cell & Gene Therapy","year":"2024","type":"Financing","leadProduct":"PROC-001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"SmartCella","amount2":0.050000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"SmartCella \/ Fj\u00e4rde AP-fonden","highestDevelopmentStatusID":"4","companyTruncated":"SmartCella \/ Fj\u00e4rde AP-fonden"},{"orgOrder":0,"company":"SmartCella","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2026","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"SmartCella","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SmartCella \/ SmartCella","highestDevelopmentStatusID":"4","companyTruncated":"SmartCella \/ SmartCella"}]

    Find Clinical Drug Pipeline Developments & Deals by SmartCella

    Menu

    SmartCella

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SmartCella

                            Sweden arrow
                            Cosmoprof
                            Not Confirmed

                            SmartCella

                            Sweden arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Preclinical

                            Recipient : Catalent Pharma Solutions

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            SmartCella, Catalent Ink License Deal for GMP iPSCs

                            Details : Through the licensing deal, an undisclosed cell & gene therapy product will be developed for cardiac disease, advancing treatment options in this area.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            January 12, 2026

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Preclinical

                            Recipient : Catalent Pharma Solutions

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SmartCella

                            Sweden arrow
                            Cosmoprof
                            Not Confirmed

                            SmartCella

                            Sweden arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PROC-001

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Preclinical

                            Sponsor : Fjärde AP-fonden

                            Deal Size : $54.1 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            SmartCella raises EUR 50 million to accelerate growth and commercialization

                            Details : The financing aims to fund the clinical development of PROC-001, which is being evaluated in the early-stage clinical trial studies for the treatment of cardiovascular diseases such as heart failure.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            July 08, 2024

                            Lead Product(s) : PROC-001

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Fjärde AP-fonden

                            Deal Size : $54.1 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.